{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:10:29Z","timestamp":1753182629712},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T00:00:00Z","timestamp":1253145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00520-009-0733-0","type":"journal-article","created":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T09:18:30Z","timestamp":1253092710000},"page":"931-942","source":"Crossref","is-referenced-by-count":2,"title":["Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study"],"prefix":"10.1007","volume":"18","author":[{"name":"on behalf of the Nord-Ostdeutschen Gesellschaft f\u00fcr Gyn\u00e4kologische Onkologie (NOGGO) working group \u201cQuality of life\u201d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Koensgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guelten","family":"Oskay-Oezcelik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Katsares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla","family":"Walle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Klapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Mustea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Stengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Porzsolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Lichtenegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,17]]},"reference":[{"key":"733_CR1","first-page":"151","volume":"55","author":"B Anderson","year":"1994","unstructured":"Anderson B (1994) Quality of life in progressive ovarian cancer. Gynecol Oncol 55:151\u2013155","journal-title":"Gynecol Oncol"},{"issue":"6","key":"733_CR2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","volume":"19","author":"K Basen-Engquist","year":"2001","unstructured":"Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al (2001) Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19(6):1809\u20131817","journal-title":"J Clin Oncol"},{"key":"733_CR3","first-page":"210","volume":"11","author":"M Bullinger","year":"1996","unstructured":"Bullinger M (1996) Methoden zur Lebensqualit\u00e4tsbewertung in der Onkologie. Forum Deutsche Krebsgesellschaft 11:210\u2013216","journal-title":"Forum Deutsche Krebsgesellschaft"},{"issue":"6","key":"733_CR4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741\u2013748","journal-title":"Int J Gynecol Cancer"},{"key":"733_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579","journal-title":"J Clin Oncol"},{"key":"733_CR6","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/0277-5379(83)90096-2","volume":"19","author":"A Coates","year":"1983","unstructured":"Coates A, Dillenbeck CF, McNeil DR et al (1983) On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 19:1633\u20131637","journal-title":"Eur J Cancer Clin Oncol"},{"key":"733_CR7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","volume":"37","author":"A Cull","year":"2001","unstructured":"Cull A, Howat S, Greimel E et al (2001) Development of a European organization for research and treatment of cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37:47\u201353","journal-title":"Eur J Cancer"},{"key":"733_CR8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/019394599701900305","volume":"19","author":"M Ersek","year":"1997","unstructured":"Ersek M, Ferrell B, Dow K et al (1997) Quality of life in women with ovarian cancer. West J Nurs Res 19:334\u2013350","journal-title":"West J Nurs Res"},{"key":"733_CR9","first-page":"32","volume":"26","author":"L Fish","year":"1999","unstructured":"Fish L, Lewis B (1999) Quality of life issues in the management of ovarian cancer. Semin Oncol 26:32\u201339","journal-title":"Semin Oncol"},{"issue":"4","key":"733_CR10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2005.02.4067","volume":"24","author":"ER Greimel","year":"2006","unstructured":"Greimel ER, Bjelic-Radisic V, Pfisterer J et al (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin\/paclitaxel versus carboplatin\/paclitaxel. J Clin Oncol 24(4):579\u2013586","journal-title":"J Clin Oncol"},{"key":"733_CR11","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","volume":"39","author":"E Greimel","year":"2003","unstructured":"Greimel E, Bottomley A, Cull A et al (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39:1402\u20131408","journal-title":"Eur J Cancer"},{"key":"733_CR12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/gyno.1993.1193","volume":"50","author":"F Guidozzi","year":"1993","unstructured":"Guidozzi F (1993) Living with ovarian cancer. Gynecol Oncol 50:202\u2013207","journal-title":"Gynecol Oncol"},{"key":"733_CR13","first-page":"1","volume-title":"Ovarian cancer: controversies in management","author":"I Jacobs","year":"1998","unstructured":"Jacobs I, van Nagell J, DePriest P Jr (1998) Screening for epithelial ovarian cancer. In: David M, Gershenson W, Mcguire P (eds) Ovarian cancer: controversies in management. Medical Division of Pearson Professional Limited, New York, pp 1\u201315"},{"issue":"7","key":"733_CR14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1701-2163(16)30609-0","volume":"26","author":"T Le","year":"2004","unstructured":"Le T, Leis A, Pahwa P et al (2004) Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment. J Obstet Gynaecol Can 26(7):627\u2013631","journal-title":"J Obstet Gynaecol Can"},{"key":"733_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01682336","volume":"4","author":"A Montazeri","year":"1996","unstructured":"Montazeri A, McEwen J, Gillis C (1996) Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer 4:169\u2013179","journal-title":"Support Care Cancer"},{"key":"733_CR16","first-page":"21","volume":"8","author":"DH Moore","year":"1994","unstructured":"Moore DH (1994) Ovarian cancer in the elderly patient. Oncology (Williston Park) 8:21\u201330","journal-title":"Oncology (Williston Park)"},{"issue":"7","key":"733_CR17","first-page":"2831","volume":"29","author":"G Oskay-Ozcelik","year":"2009","unstructured":"Oskay-Ozcelik G, Sehouli J (2009) Pros and cons for systemic therapy in recurrent ovarian cancer. Anticancer Res 29(7):2831\u20132836","journal-title":"Anticancer Res"},{"key":"733_CR18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO;2-#","volume":"74","author":"R Portenoy","year":"1994","unstructured":"Portenoy R, Kornblith A, Wong G (1994) Pain in ovarian cancer patients. Cancer 74:907\u2013915","journal-title":"Cancer"},{"key":"733_CR19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","volume":"30A","author":"R Portenoy","year":"1994","unstructured":"Portenoy R, Thaler H, Kornblith A (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326\u20131336","journal-title":"Eur J Cancer"},{"key":"733_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219\u2013227","journal-title":"Support Care Cancer"},{"issue":"24","key":"733_CR21","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1200\/JCO.2005.08.147","volume":"23","author":"L Wenzel","year":"2005","unstructured":"Wenzel L, Huang HQ, Monk BJ et al (2005) Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 23(24):5605\u20135612","journal-title":"J Clin Oncol"},{"key":"733_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0277-5379(90)90232-I","volume":"26","author":"P Willemse","year":"1990","unstructured":"Willemse P, van Lith J, Mulder N (1990) Risk and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer 26:345\u2013352","journal-title":"Eur J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0733-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0733-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0733-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:01:55Z","timestamp":1559080915000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0733-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,17]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0733-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2009,9,17]]}}}